Prof Anthony Wiezbicki, Guy’s and St Thomas’ NHS Foundation Trust, London UK gives his view on how these novel PCSK9 therapeutics will be used in real-world clinical settings.
How will PCSK9 inhibitors be used in practice?
www.pcsk9forum.org/how-will-pcsk9-inhibitors-be-used-in-practice/
What are the patient priorities for PCSK9 inhibitors?
www.pcsk9forum.org/what-are-the-patient-priorities-for-pcsk9-inhibitors/
FH: Start treatment early: Maximise benefit
www.pcsk9forum.org/start-treatment-early-maximise-benefit/
The role of PCSK9 inhibitors in FH
www.pcsk9forum.org/dr-dirk-blom-south-africa-the-role-of-pcsk9-inhibitors-in-fh/
Weighing the cost versus benefit of PCSK9-targeted therapy
www.pcsk9forum.org/weighing-the-cost-versus-benefit-of-pcsk9-targeted-therapy/
PCSK9 INHIBITION: New Therapies in Cardiovascular Risk Reduction
www.pcsk9forum.org/pcsk9-inhibition-new-therapies-in-cardiovascular-risk-reduction/
Impact on CHD risk:
www.pcsk9forum.org/acc-2015-what-do-the-osler-and-odyssey-data-really-show-expert-analysis-from-professor-derick-raal/
Impact on guidelines?
www.pcsk9forum.org/high-intensity-cholesterol-lowering-therapy-versus-high-intensity-statin-therapy/
